CD44S-TARGETED TREATMENT WITH MONOCLONAL ANTIBODY BLOCKS INTRACEREBRAL INVASION AND GROWTH OF 9L GLIOSARCOMA

摘要: Glioma invasiveness is a complex process involving recognition and attachment of tumor cells to particular extracellular matrix (ECM) molecules prior migrating into proteolytically modified inducing angiogenesis. CD44 group transmembrane adhesion found on wide variety including gliomas that has been suggested as the principal mediator migration/invasion. The aim present study was demonstrate whether antibody specific for standard form (CD44s, 85–90 kDa) might prevent invasion, thus blocking growth 9L gliosarcoma in vivo. High expression CD44s surface brain tumors demonstrated by immunochemistry. Fluorescence-activated cell sorting (FACS) binding saturation anti-CD44s monoclonal (mAb) receptor at 1 μg/5 × 105 cells. Blocking in vitro resulted dose-dependent progressive, up 95% ± 2.5% detachment from ECM-coated culture surfaces. vivo significantly reduced (2.5% 0.4%) – measured quotient: (mm2)/brain (mm2) 100 compared untreated (16.1% 2.2%) or sham-treated rats (16% 3.7% 16.1% 3%). We conclude CD44s-targeted treatment with mAb may be an effective means preventing glioma progression.